Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN(a)-CCTA: Olpasiran (AMG 890) in stable atherosclerotic cardiovascular disease with elevated lipoprotein(a)
CTR20260248Phase 3Active
- Sponsor
- Amgen
- Start
- Apr 2026
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of olpasiran in atherosclerotic disease, coronary arteriosclerosis, lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Amgen. Started Apr 2026; status: active.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseasecoronary arteriosclerosislipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on CTR20260248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260248.